Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | LIPC | P11150 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14019651 | 0.89 | CNR2 (0.40) | RXFP1CNR2LMNAATMCNR1 | |
| SCHEMBL14019666 | 0.88 | CNR2 (0.42) | RXFP1CNR2CNR1 | |
| SCHEMBL1132860 | 0.87 | LMNA (0.46) | RXFP1MEN1KMT2AMAPTLMNA | |
| SCHEMBL14019657 | 0.84 | RXFP1 (0.34) | RXFP1MEN1KMT2ACNR2MAPT | |
| SCHEMBL4030026 | 0.80 | KDM4E (0.42) | TOP1LMNAALDH1A1 | |
| SCHEMBL13799088 | 0.79 | KDM4E (0.42) | TOP1LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL3288212 | 0.78 | KDM4E (0.41) | TOP1LMNAALDH1A1 | |
| SCHEMBL3293923 | 0.78 | P2RY14 (0.39) | TOP1MEN1KMT2ACNR2LMNA | |
| SCHEMBL14019668 | 0.76 | CNR1 (0.39) | MEN1KMT2ACNR2LMNAALDH1A1 | |
| SCHEMBL4964051 | 0.76 | CHRNB2 (0.40) | ACHECNR2LMNAALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269146-A1 | 4''-Substituted Erythromycin Derivative | GLAXO GROUP LIMITED | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269146-A1 | 4''-Substituted Erythromycin Derivative | MRPL21, CYP3A4, CYP51A1 | TOP1 2185/4885RXFP1 2725/4885MEN1 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.